Lantern Pharma (LTRN) News Today $3.99 -0.29 (-6.78%) Closing price 04:00 PM EasternExtended Trading$4.04 +0.04 (+1.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period IBN Initiates Coverage of Lantern Pharma Inc.July 16 at 9:54 PM | finance.yahoo.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15 at 9:23 PM | theglobeandmail.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15 at 9:40 AM | businesswire.comNASDAQ:LTRN Financials | Lantern Pharma Inc - Investing.comJuly 9, 2025 | investing.comLantern Pharma Enters ATM Sales Agreement with ThinkEquityJuly 3, 2025 | tipranks.comLung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two YearsJune 16, 2025 | businesswire.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 40,000 SharesJune 14, 2025 | insidertrades.comHere's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn SituationMay 31, 2025 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $43,050.00 in StockMay 30, 2025 | insidertrades.comLantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor ModelsMay 29, 2025 | insidermonkey.comLantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical TrialsMay 29, 2025 | businesswire.comLTRN: First Quarter 2025 Financial ResultsMay 20, 2025 | finance.yahoo.comEarnings call transcript: Lantern Pharma Q1 2025 reports narrower lossMay 17, 2025 | uk.investing.comLantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comLantern Pharma Inc. (LTRN) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comLantern Pharma Reports First Quarter 2025 Financial Results and Business UpdatesMay 15, 2025 | businesswire.comLantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ETMay 8, 2025 | businesswire.comLTRN: IND Clearance for LP-184 in TNBCMay 6, 2025 | msn.comLantern Pharma Stock Short Interest Report | NASDAQ:LTRN | BenzingaMay 6, 2025 | benzinga.comEXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage TrialMay 5, 2025 | uk.finance.yahoo.comLantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)May 5, 2025 | businesswire.comLantern Pharma initiated with a Buy at Lake StreetApril 3, 2025 | markets.businessinsider.comLake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy RecommendationApril 3, 2025 | msn.comEarnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expensesMarch 29, 2025 | uk.investing.comLTRN: 2024 Financial ResultsMarch 28, 2025 | finance.yahoo.comLantern Pharma outlines 2025 clinical milestones and key updates on oncology trialsMarch 27, 2025 | msn.comLantern Pharma Inc. (LTRN) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comLantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial ResultsMarch 27, 2025 | businesswire.comPreview: Lantern Pharma's EarningsMarch 27, 2025 | benzinga.comLTRN: M&A Illuminates GBM ValueMarch 10, 2025 | finance.yahoo.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | insidermonkey.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | msn.comLantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer TherapiesJanuary 27, 2025 | insidermonkey.comLantern Pharma Inc. (LTRN): AI-Driven Cancer Drug DevelopmentJanuary 17, 2025 | insidermonkey.comIs Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?December 22, 2024 | finance.yahoo.comAI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in TaiwanDecember 10, 2024 | insidermonkey.comLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONICâ„¢ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsDecember 9, 2024 | businesswire.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | insidermonkey.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | msn.comLantern Pharma Shares Rise After Fast-Track Designation for Cancer TreatmentDecember 4, 2024 | marketwatch.comLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)December 4, 2024 | businesswire.comLantern Pharma doses first patient in LP-300 trial expansion cohortNovember 20, 2024 | markets.businessinsider.comLTRN: Pediatric Rare Cancer in FocusNovember 12, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comLantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...November 9, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLantern Pharma Advances AI-Driven Cancer TherapiesNovember 8, 2024 | markets.businessinsider.comLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 7, 2024 | businesswire.comStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNovember 5, 2024 | finance.yahoo.comLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETOctober 31, 2024 | businesswire.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.140.96▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼31▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYBN News DMAC News NVCT News PBYI News ACRS News ENGN News CCCC News ACOG News BDTX News ALEC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTRN Stock Alerts